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Abstract
Circadian genes have the potential to influence a variety of cancer-related biological pathways,
including immune regulation, which may influence susceptibility to non-Hodgkin’s lymphoma
(NHL). However, few studies have examined the role of circadian genes in lymphomagenesis. The
current study examined Cryptochrome 2 (CRY2), a core circadian gene and transcriptional
repressor, as a potential circadian biomarker for NHL. We first performed genetic association
analyses of tagging SNPs in CRY2 and NHL risk using DNA samples from a population-based
case-control study (N= 455 cases and 527 controls). Three SNPs were found to be significantly
associated with risk of NHL when combining all subtypes (dbSNP IDs, odds ratios (ORs), and
95% confidence intervals: rs11038689, OR=2.34 (1.28-4.27), P=0.006; rs7123390, OR=2.40
(1.39-4.13), P=0.002; and rs1401417, OR=2.97 (1.57-5.63), P=0.001). Each of these associations
remained significant when restricting the analysis to B-Cell cases and when further restricting to
follicular lymphomas. An analysis of CRY2 diplotypes confirmed these significant findings. To
further determine the functional impact of CRY2, we silenced the gene in vitro and performed a
whole genome expression microarray. A pathway-based analysis showed that genes significantly
altered by CRY2 knockdown formed networks associated with immune response and
hematological system development. In addition, these genes were predicted to have significant
impacts on several disease processes, including cancer (B-H P-value=3.75E-9) and hematological
disease (B-H P=8.01E-8). In conclusion, both genetic association and functional analyses suggest
that the circadian gene CRY2 may play an important role in NHL development.
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Introduction
The human circadian rhythm is a fundamental aspect of human physiology, and a wide
range of biological processes are influenced by the circadian clock, including body
temperature, energy metabolism, hormone secretion, and sleep-wake cycles (1). Several
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observational studies indicate that individuals who do not maintain a normal sleep/wake
cycle may be at increased risk for several cancer types, and after considering evidence from
epidemiologic and experimental studies, the International Agency for Research on Cancer
(IARC) recently concluded that shift work that involves circadian disruption is “probably
carcinogenic to humans” (2). Although much of the current epidemiologic evidence has
focused on breast cancer, it has recently been hypothesized that circadian disruption may
also affect risk for NHL, possibly through its influence on immune regulation (3).
Limited indirect evidence suggests that genetic components of the circadian system may
have a role in processes relevant for NHL tumorigenesis. For example, reduced expression
of the circadian gene PER2 has been detected in lymphoma cell lines and in samples drawn
from patients with acute myeloid leukemia (AML) (4), and a recent genetic association
study demonstrated that a non-synonymous polymorphism in the core circadian gene NPAS2
is associated with decreased risk of NHL, especially B-cell lymphoma (5). In addition,
several studies have established an important role for circadian rhythm in the maintenance of
proper immune function. First, it has been shown that several key components of the
immune system are under circadian regulation, with circadian rhythmicity present in nearly
all aspects of immune response (6-11). Specifically, circadian rhythms have been observed
in natural killer (NK) cells, which are an essential component of the innate immune system
against infections and cancerous growth (12). Secondly, disruption of circadian rhythms can
cause aberrant immune cell trafficking and abnormal cell proliferation cycles (13).
Moreover, disruption of the circadian rhythms in NK cells and phagocytic activity has been
observed in malignant melanoma cells, leading to a discoordination between the two
immune system components that is not observed in healthy humans (14).
Overall, these preliminary studies suggest that circadian disruption has the potential to
significantly impact a number of mechanisms that may influence NHL susceptibility, most
notably through its role in influencing immune response. However, while immune
dysfunction remains the only well-established risk factor for NHL (15, 16),
immunodeficiency is seen only in a subset of NHL patients. As such, if an association
between circadian disruption and lymphomagenesis can be firmly established, there remains
the additional question of whether the relationship is maintained outside of pathways related
to immune system function. Further study into these associations is therefore warranted and
are apropos to investigations into the potential for circadian gene variants to serve as a novel
panel of NHL risk biomarkers.
The current study investigates the role of the core circadian gene CRY2 in NHL
tumorigenesis. CRY2 is essential to the maintenance of circadian rhythm through its role in
the negative arm of the circadian feedback loop, and may have a broader regulatory role as a
transcriptional repressor (17, 18). CRY2 has also been shown to be involved in cell cycle
regulation, including roles in DNA damage checkpoint control (19) and regulation of genes
important for cell cycle progression (20). Here, we report findings from an epidemiological
analysis of the association between genetic variants in CRY2 and risk of NHL. In addition,
we performed a whole genome expression microarray to determine the effect of CRY2
silencing on the expression of cancer-related genes, and to determine whether CRY2
influences biological pathways which may be relevant for lymphomagenesis.
Patients, materials, and methods
Case-control study of NHL
The study population has previously been described (21). Briefly, all participants were
female residents of Connecticut, and cases were incident, histologically-confirmed NHL
(ICD-O, M-9590-9642, 9690-9701, 9740-9750) identified through Yale Cancer Center’s
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Rapid Case Ascertainment (RCA) between 1996 and 2000. Population-based controls
younger than age 65 were recruited by random digit dialing (RDD), and controls older than
65 were identified through Health Care Financing Administration files. Five year age strata
were constructed, and controls were frequency matched to cases by intermittently adjusting
the number of controls selected from each stratum. Participation rates were: 72% for cases,
69% for RDD controls, and 47% for controls identified by health care financing records.
Data collection
The study was approved by Institutional Review Boards at Yale University, the Connecticut
Department of Public Health, and the National Cancer Institute. Participation was voluntary,
and written informed consent was obtained. Those who agreed were interviewed by trained
study nurses either at the subject’s home or at a convenient location, and following the
administration of a questionnaire, subjects provided a 10 ml peripheral blood sample.
Genomic DNA was isolated from peripheral blood lymphocytes for each study subject.
SNP selection and genotyping
SNPs were identified using the Tagger algorithm (22), which is implemented in the
Haploview interface (23) of HapMap’s genome browser, Release 22
(http://www.hapmap.org/cgi-perl/gbrowse/hapmap22_B36/ accessed on January 15, 2008).
Five SNPs (rs10838524, rs11038689, rs11605924, rs2292912, and rs7123390) were
identified as representative of all variations found within the exonic and intronic regions of
the CRY2 gene using the CEU population returning SNPs with MAF ≥ 0.2 and r2 ≥ 0.8. In
addition, one intronic SNP (rs1401417) which had been identified as significantly associated
with prostate cancer risk in a previous study (24) was also included in the genotyping pool.
Genotyping for all SNPs was performed at Yale University’s W.M. Keck Foundation
Biotechnology Research Laboratory using the Sequenom MassARRAY multiplex
genotyping platform (Sequenom, Inc., San Diego, CA) according to the manufacturer’s
protocol. Duplicate samples from 100 study subjects and 40 replicate samples from each of
two blood donors were interspersed throughout each batch for all genotyping assays.
Genotyping failed for one SNP (rs10838524). The concordance rates for QC samples were
over 95% for the remaining assays. Genotyping call rates were: 97.0% for rs11038689,
97.5% for rs11605924, 97.7% for rs2292912, 96.6% for rs7123390, and 97.8% for
rs1401417. All genotyping scores, including quality control data, were re-checked by
different laboratory personnel and the accuracy of each assay was confirmed.
Cell culture and treatments
Human breast adenocarcinoma cells (MCF-7) were used to determine the impact of CRY2
knockdown on pathways related to lymphomagenesis. MCF-7 cells were chosen rather than
cells derived from lymphoma tissue, as lymphoma cells would likely begin with aberrant
immune signaling, thus causing difficulty in interpreting the effects of CRY2 knockdown on
immune regulation. Cells were obtained from American Type Culture Collection (Manassas,
VA), and were maintained in Dulbecco’s modified Eagle medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum (Invitrogen), 0.01 mg/ml bovine insulin,
and 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, MO). siRNA oligos targeting
CRY2 (Sense: 5’-UGCUUCAUUCGUUCAAUGUUAAGCCGG-3’ Antisense: 5’-
GGCUUAACAUUGAACGAAUGAAGCA-3’) and a scrambled sequence negative control
siRNA (Sense: 5’-CUUCCUCUCUUUCUCUCCCUUGUGA-3’, Antisense: 5’-
UCACAAGGGAGAGAAAGAGGGAAGGA-3’) were designed and manufactured by
Integrated DNA Technologies (IDT, Coralville, IA). Each oligo was diluted in OPTI-MEM
serum-free medium (Invitrogen), complexed with Lipofectamine RNAiMax transfection
reagent (Invitrogen), and reverse transfected with approximately 100,000 cells in 12 well
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plates at a final concentration of 10nM in growth medium without penicillin/streptomycin.
Cells were harvested 48 hours after transfection for subsequent analysis.
RNA isolation and quantitation
CRY2 silencing efficiency was determined by qPCR of RNA samples isolated using the
RNA Mini Kit (Qiagen, Valencia, CA), with on-column DNA digestion, according to the
manufacturer’s instructions for mammalian cells. First-strand cDNA was synthesized from
purified RNA using the AffinityScript cDNA kit (Stratagene, La Jolla, CA) with oligo-dT
primers. Quantitative real-time PCR conditions were prepared using a SYBR Green PCR
master mix (Applied BioSystems, Foster City, CA) with gene-specific primers, and a
standard thermal cycling procedure on an ABI 7500 instrument (Applied BioSystems). The
primers used for CRY2 amplification were: (L: ACCGGGGACTCTGTCTACTG, R:
GCCTGCACTGCTCATGCT). CRY2 knockdown was assessed using the 2-ΔΔCt method
with RNA content normalized to the housekeeping gene HPRT1.
Gene expression microarray and pathway analysis
Gene expression differences in CRY2 knockdown and normal cells were interrogated by
whole genome microarray (Agilent, Inc 41k chip, performed by MoGene, LC, St Louis,
MO). RNA was isolated in duplicate (biological replicates) from cells treated with CRY2-
targeting or scrambled negative siRNA. Transcripts were identified as “differentially
expressed” if they fit the criteria of Benjamini-Hochberg adjusted P-value < 0.01 in both
biological replicates and mean fold change > |2|. Transcripts with differential expression
were investigated for network and functional inter-relatedness using the Ingenuity Pathway
Analysis software tool (Ingenuity Systems, www.ingenuity.com). This software scans the
set of input genes to identify networks using information in the Ingenuity Pathways
Knowledge Base, an extensive, manually curated database of functional interactions
extracted from peer-reviewed publications (25). A Fisher’s exact test, based on the
hypergeomtric distribution, is then performed to determine the likelihood of obtaining at
least the same number of molecules by chance (i.e. from a random input set), as actually
overlap between the input gene set and the genes present in each identified network. All
microarray data has been uploaded to the Gene Expression Omnibus (GEO) database. Raw
and processed data related to this experiment can be accessed via their website
(http://www.ncbi.nlm.nih.gov/projects/geo/) by referencing accession #GSE14617.
Statistical analysis
All statistical analyses were performed using the SAS statistical software (SAS Institute,
Cary, NC), unless otherwise noted. For the case-control analyses, allelic distributions for all
SNPs were tested by goodness-of-fit chi-square for compliance with Hardy-Weinberg
equilibrium (HWE). A chi-square test was also used to determine whether any of the
variants were associated with case-control status, using either the full table (homozygous
wild-type, heterozygous, and homozygous variant), a dominant model, or a recessive model.
Odds ratios and 95% confidence intervals were determined for each SNP-disease association
by unconditional multivariate logistic regression, including the following covariates: age,
race, and family history of cancer in a first-degree relative. Haplotype estimates were
calculated by the PHASE program, which reconstructs haplotypes from population
genotyping data (26). Diplotypes were constructed based on the pair of haplotypes estimated
for each individual, and odds ratios and 95% confidence intervals for each diplotype were
determined by unconditional multivariate logistic regression, using the same covariates as
the main effects model, but with all other diplotypes as the referent category.
Due to the multiple comparisons inherent in the microarray analysis, adjustments were made
to control for false discoveries. A multiple comparisons correction was applied to each
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observation using the Benjamini-Hochberg method, as previously described (27), to obtain
an adjusted p-value (B-H P-value). Alpha was set at 0.01, and in order to be considered
statistically significant.
Results
Association between CRY2 variants and NHL risk
Compared to controls, NHL cases reported a higher proportion of NHL and other cancers
among first-degree relatives. There were no significant differences in age and race between
cases and controls (Table 1). Genotypic frequencies were determined at each locus, and no
allelic distributions significantly departed from the values expected under HWE among the
controls (p<0.01). Three of the five SNPs: rs11038689, rs7123390, and rs1401417 were
found to be significantly associated with case-control status in the overall three-by-two table
of allele distribution vs. case-control status (Supp. Table 1), with p-values of 0.005, 0.003,
and 0.004, respectively for the two degrees of freedom chi-square test. Each of the three
SNPs significantly associated with disease status in the full table was also significant when a
recessive model was assumed, but not when assuming a dominant model. As such, odds
ratios and confidence intervals were determined by unconditional multivariate logistic
regression under the assumption of a recessive model. Variant alleles in the same three SNPs
(rs11038689, rs7123390, and rs1401417) which were associated with case-control status in
the unadjusted chi-square analysis were also significantly associated with increased risk of
NHL in the adjusted logistic regression model, with ORs (95%CIs) of 2.34 (1.28-4.27,
p=0.006), 2.40 (1.39-4.13, p=0.002), and 2.97 (1.57-5.63, p=0.001), respectively (Table 2).
Since NHL is comprised of various subtypes with the potential for distinct etiologies, we
also performed a stratified analysis including B-cell and T-cell lymphomas only. These
results were qualitatively and quantitatively similar to those obtained in the overall analysis
with ORs (95% CIs) for homozygous variants of rs11038689, rs7123390, and rs1401417
among B-cell lymphomas only of: 2.35 (1.25-4.41, p=0.008), 2.54 (1.44-4.46, p=0.001), and
2.87 (1.47-5.58, p=0.002), respectively. Although similar point estimates for the odds ratios
were observed among T-cell lymphomas only, only rs1401417 reached statistical
significance (OR=4.64 (1.41-15.34, p=0.012)) due to the small sample size. Further
stratification was performed to analyze four common subtypes of B-cell lymphoma (Table
3). Each of the SNPs significantly associated with lymphoma in the full population
(rs11038689, rs7123390, and rs1401417), was also significantly associated with follicular
lymphoma (FL), with ORs (95% CIs) of: 3.17 (1.39-7.19, p=0.006), 3.67 (1.79-7.56,
p<0.001), and 3.06 (1.24-7.54, p=0.015), respectively. Two SNPs, rs7123390 and rs1401417
were significantly associated with B-cell chronic lymphocytic leukemia/prolymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), with ORs (95% CIs) of: 3.38
(1.35-8.45, p=0.009) and 4.23 (1.53-11.67, p=0.005), respectively. Only rs1401417 was
significantly associated with diffuse large B-cell lymphoma (DLBCL; OR=2.67 (1.13-6.33,
p=0.026)). Very few patients were classified as having marginal zone B-cell lymphoma
(MZBL), and no CRY2 SNPs were significantly associated with this NHL subtype.
Association between CRY2 diplotypes and NHL risk
To further explore the relationship among SNPs, haplotypes were estimated for these five
SNPs and thirteen different haplotypes were identified among all subjects (Supp. Table 2).
Nine haplotypes carried at least one risk allele (i.e. a variant associated with increased risk in
the main effects analysis). Since the individual risk estimates indicated a recessive disease
model, we used the haplotype information to construct diplotypes for each individual. Figure
1 depicts the location of each marker within the CRY2 gene, and shows the NHL subtypes
which were significantly associated with each homozygous variant diplotype. Full results
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are provided in the supplementary material (Supp. Table 3). ORs (95% CIs) for homozygous
variant diplotypes of rs11065924, rs11038689, rs2292912, rs1401417, and rs7123390 using
the full population were: 0.81 (0.61-1.08), 2.32 (1.27-4.24), 0.96 (0.53-1.75), 2.81
(1.51-5.23), and 2.36 (1.39-4.02), respectively. The odds ratio associated with having the
homozygous variant diplotype at one or more of the risk loci (rs11038689, rs1401417, or
rs7123390) was 2.72 (1.61-4.59).
Microarray reveals several cancer- and immune-related genes which are influenced by
CRY2
In order to determine which genes and biological pathways might be influenced by CRY2,
we silenced the gene in vitro, and performed a whole genome array comparing gene
expression in cells with reduced CRY2 to cells with normal CRY2 levels. 734 differentially
expressed transcripts were identified (B-H P-value<0.01 in both biological replicates and
mean fold change>|2|), and these genes were further explored through pathway and
functional analyses using the IPA software package. 23 networks were identified as
significantly associated with the differentially expressed genes at P less than 1.0E-10.
Among these, 7 were associated with Cancer, 6 networks were important for Immune
Response, and 4 were important for Hematological System Development or Hematological
Disease (Supp. Table 4).
The top network operative in Hematological System Development and Function (p=1.0E-36,
Figure 2) also contained several cancer-related transcripts, including molecules important
for DNA repair, cell migration and metastasis, apoptosis, cell proliferation, and
angiogenesis. The details of each transcript in the network, including fold changes, adjusted
P-values, and a short description of function with relevant citations, can be found in the
supplementary material (Supp. Table 5). Briefly, 35 genes were present in the network, 33
of which could be uniquely associated with a single transcript in the microarray. Of these, 27
were significantly upregulated following CRY2 silencing, 4 were not significantly altered,
and only 2 were significantly downregulated; which is consistent with CRY2’s role as a
transcriptional repressor. The probability of obtaining at least this many differentially
expressed molecules in one network by chance alone is reflected by the P-value for the
network (P=1.0E-36), indicating that it is very unlikely that the network was obtained
randomly, and therefore CRY2 is likely to be important for immune response coordination
and processes related to hematological system development. At the center of this network is
interleukin-6 (IL-6), an immunoregulatory cytokine that is important for cell growth. This
transcript was strongly upregulated following CRY2 silencing, with a mean fold increase of
8.17 (B-H P=0). In addition, a member of the vascular endothelial growth factor family
(VEGFC), which is also important for cell growth, as well as angiogenesis, was upregulated
more than 6-fold (B-H P=6.99E-4). Interestingly, a number of transcripts with pro-apoptotic,
anti-proliferative, or other tumor suppressor capabilities were also upregulated in this
network. These include Interferon Beta 1 (IFNB1) which was upregulated more than 3-fold
(B-H P=2.96E-9), thioredoxin interacting protein (TXNIP), greater than 11-fold upregulated
(B-H P=2.47E-4), retinoic acid receptor responder 3 (RARRES3), greater then 2-fold
upregulated (B-H P=1.86E-4), and two members of the chemokine (C-X-C motif) ligand
family (CXCL9 and CXCL11), greater than 10- and 4-fold upregulated, respectively (B-H
P=1.01E-5 and=3.04E-6).
Apart from the transcripts in this network, several additional genes which may be relevant
for lymphomagenesis were identified as significantly altered following CRY2 silencing.
These include three members of the chemokine (C-C motif) ligand family (CCL3, CCL4,
and CCL5), which are important for immune regulation and inflammatory processes; several
additional members of the interleukin family of cytokines (including IL-11, IL-15, IL-18,
IL-28a, IL-28b, and IL-29,); two insulin-like growth factor binding proteins (IGFBP3 and
Hoffman et al. Page 6
Cancer Res. Author manuscript; available in PMC 2011 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
IGFBP6); and genes in the major histocompatibility complex, class I (HLA-A, HLA-B,
HLA-C and HLA-E). Of note, CRY2 itself was significantly downregulated in both
microarray replicates (B-H P<0.05), with exactly the same fold change of -3.17 observed in
both samples.
The program also computes a P-value based on the likelihood of obtaining the observed
number of differentially expressed molecules in a given process by chance alone. The top
three disease processes associated with the differentially expressed gene set were “Cancer”
(B-H P=3.75E-9), “Inflammatory Disease” (B-H P=5.19E-8), and “Hematological Disease”
(B-H P=8.01E-8) (Figure 3). In addition, 144 of the differentially expressed transcripts were
related to “Tumorigenesis” (B-H P=4.57E-9), 64 molecules were associated with “Immune
Response” (B-H P=7.03E-10), and 49 were involved in “Proliferation of Lymphocytes” (B-H
P=6.76E-9). The large number of cancer- and immune-related molecules influenced by
CRY2 knockdown provides further evidence suggesting a role for CRY2 in
lymphoproliferative processes.
Discussion
The observed connection between circadian disruption (e.g. shift work) and cancer risk in
epidemiologic studies has led to the circadian gene hypothesis, which suggests that genetic
variants in genes responsible for maintaining circadian rhythm may affect an individual’s
susceptibility to human cancers. This hypothesis is supported by results from recent genetic
association studies of breast cancer (28, 29), prostate cancer (24), and NHL (5). The findings
from the current study of CRY2 provide more evidence demonstrating a role for the
circadian genes in NHL susceptibility.
To the best of our knowledge, genetic variants in CRY2 have not been previously examined
in NHL, and only one of the SNPs genotyped in the case-control portion of this analysis had
been studied previously; in a population-based case-control study conducted in China, which
showed a significant association between the variant allele of rs1401417 and increased risk
of prostate cancer (24). This finding is consistent with the significant association we
observed in the NHL population, and further investigations into the nature of these
relationships are warranted in order to determine whether CRY2 has a global impact on
cancer susceptibility.
The observed associations between CRY2 and NHL risk provide additional molecular
epidemiologic evidence supporting the proposed role of circadian genes as tumor
suppressors (30). Circadian genes have been shown to affect expression of 2–10% of
mammalian genes (31) including many cancer-related genes (30). Emerging data from
animal models have further demonstrated a substantial impact of circadian genes on tumor-
related biological pathways such as cell proliferation, cell cycle control, DNA damage
response, and apoptosis (30). Mice with mutations in the circadian gene PER2 have
deficiencies in DNA damage response and are more prone to tumorigenesis (32). Altered
expression of circadian genes also occurs in human tumors; as studies have shown that the
period (PER) genes fail to maintain daily rhythmic expression patterns in cancer cells (33).
Although CRY2 has also been shown to be involved in cell cycle regulation (34), explicit
mechanisms for its role in cancer susceptibility, especially NHL tumorigenesis, are currently
unknown.
The microarray analysis, which implicated CRY2 as having the potential to influence gene
expression in a number of pathways, including those with relevance for cancer and immune
function, provides the first mechanistic evidence suggesting that CRY2 may be important for
NHL susceptibility. The findings relative to IL-6 are of particular interest. It has been
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demonstrated that IL-6 can inhibit DNA synthesis by preventing cell cycle progression into
S phase (35). It has also been fairly well established that IL-6 plays an important role in B-
cell proliferation (36), and antibodies against IL-6 or its receptor have been explored as
treatments for B-lymphoproliferative disorder (37) and inflammatory autoimmune diseases
(38). In addition, a previous study has demonstrated that mice expressing an IL-6 transgene
exhibit lymphoproliferation and plasmacytosis, and nearly a third of these mice developed
follicular and diffuse large cell B-cell lymphomas (39). Moreover, serum levels of IL-6 and
VEGF have been shown to be of value in predicting clinical outcome in some patients with
NHL (40, 41). The observation that silencing of CRY2 results in more than 8-fold induction
of IL-6, and 6-fold induction of VEGFC, is therefore highly relevant in understanding the
etiology of hematologic malignancies, and may have important implications for predicting
NHL prognosis. Furthermore, cell signaling by IL-6 is partially mediated by its effects on
the JAK/STAT3 pathway (42). While JAK was unaffected following CRY2 silencing,
STAT3 was upregulated more than twofold (B-H P=7.06E-5). Since IL-6 has been shown to
confer increased survival and chemotherapeutic resistance on lymphoma cells, which is at
least partially mediated by STAT3; STAT3 has been proposed as a potential therapeutic
target for patients with NHL (43). As such, although the pleiotropic biological effects of
CRY2 may make it a poor candidate to be directly targeted by therapeutic agents, its effects
on both IL-6 and STAT3 may lead future investigations to consider circadian timing when
administering cytokine-targeting chemotherapies.
Apart from IL-6, several other interleukins were also significantly altered in CRY2
knockdown cells. IL-18, which was upregulated by more than 10 fold, may play an
important, but paradoxical role in cancer risk (44). It has been implicated in cancer
protection, through its role in activating immune cells to eliminate sporadic cancers, but may
also promote tumor progression by encouraging angiogenesis, tumor growth and local
invasion. Interestingly all three members of a newly described class of interferon lambdas
(IL-28a, IL-28b, and IL-29) were significantly upregulated following CRY2 silencing. These
immunoregulatory cytokines have antiviral and antitumor activity, and may also have
potential as therapeutic agents in the treatment of cancer (45).
Three members of the chemokine (C-C motif) ligand family (CCL3, CCL4, and CCL5) were
also upregulated in CRY2 knockdown cells. These genes are clustered together on the long
arm of chromosome 17, and are important for immune regulation and inflammation (46).
CCL3, which was upregulated more than 15 fold in CRY2 knockdown cells, has been shown
to be elevated in patients with multiple myeloma (MM) and other hematologic cancers
compared to healthy controls; and increased serum levels of CCL3 were associated with
advanced MM stage (47) and poorer prognosis in MM (48). Of additional interest was the
identification of four genes in the major histocompatibility complex, class I (HLA-A, HLA-
B, HLA-C, and HLA-E), which were all significantly upregulated following CRY2 silencing.
Apart from being central to immune regulation, these genes have been associated with
several cancers, including Hodgkin’s disease (49) and non-Hodgkin’s lymphoma (50).
Taken together, these results suggest that reductions in CRY2 have the potential to
significantly impact processes relevant for lymphomagenesis, and while they represent a
first step in understanding the mechanism by which SNPs in the CRY2 gene might influence
NHL susceptibility.
It is important to recognize some of the study’s limitations. First, it is unclear how closely
the effect of CRY2 silencing in vitro might mimic the conditions which would arise in vivo.
At the level of the organism, circadian rhythmicity is made even more complex by
environmental cues, such as light exposure, and hormonal pathways, which may influence
circadian gene expression. In addition, since one aim of the study was to examine the
influence of CRY2 silencing on immune response pathways, we chose not to use cells
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derived from lymphoma tissue, which may begin with some level of aberrant immune-
related gene expression. As such, it will be necessary for future studies to confirm that the
findings we observed are applicable to lymphocytes, and that the changes in gene expression
following CRY2 silencing that we observed at the cellular level, are representative of those
that would occur at the organismal level.
In summary, the findings from our case-control analysis suggest a novel association between
the circadian gene CRY2 and risk of NHL; supporting the hypothesis that genetic variations
in circadian genes may confer inherited susceptibility to NHL. The subsequent loss-of-
function analysis and whole genome expression microarray suggest that the observed
association could potentially be attributed to the impact of CRY2 on several genes important
for cancer in general, as well as a number of genes with known relevance for hematological
malignancies. Our findings provide a novel panel of promising biomarkers for NHL risk and
prognosis, which warrant further investigation. In addition, since previous studies have
suggested that circadian-related environmental exposures, such as light at night or rotating
shift work, may influence cancer susceptibility, future investigations into potential
interactions between circadian gene variants and environmental exposures may be of interest
in developing cancer prevention strategies.
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Figure 1. Diplotype analysis and location of CRY2 variants
Haplotypes were estimated for each individual using the PHASE program, and diplotypes
were constructed by combining the two haplotype estimates for each individual. Since the
main effects associations indicated a recessive disease model, risk estimates were calculated
for all combinations of haplotypes resulting in a homozygous variant diplotype at each
locus, with all other diplotypes as the reference category. Estimates were obtained for each
NHL subtype represented in the population, and homozygous diplotypes which were
significantly associated with each subtype (p<0.05) are depicted with a plus symbol, while
nonsignifcant associations are shown as a minus. “1+ risk variant” refers to any haplotype
combination which resulted in a homozygous variant diplotype for at least one of the
following makers: rs11038689, rs1401417, or rs7123390.
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Figure 2. Network of interactions among genes differentially expressed following CRY2
knockdown
This network was identified as operative in Immune Response, Cell-to-Cell Signaling and
Interaction, and Hematological System Development and Function, as determined by
Ingenuity Pathway Analysis software. Each shaded transcript was significantly altered
following CRY2 silencing, with a mean fold change>|2| and B-H P-value <0.01 in both
biologic replicates of the whole genome microarray. Genes depicted in red are upregulated,
while those in green are downregulated. Higher intensity color corresponds to greater
magnitude of the fold change. Of the 29 molecules in the network which were significantly
altered 27 were upregulated, while only 2 were downregulated; which is consistent with
CRY2’s role as a transcriptional repressor.
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Figure 3. Diseases most strongly associated with the significantly altered genes
The Ingenuity software scans its Knowledge Base of manually curated relationships for
instances in the literature which can link a specific molecule to a functional disease process.
The software also assigns a P-value based on the likelihood of obtaining the observed
number of disease-related molecules in a given dataset by chance alone. Due to the large
number of disease processes represented in the database, B-H P-values are presented to
correct for multiple comparisons. The threshold line indicates a B-H P-value of 0.05.
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Table 1
Distribution of selected characteristics by case-control status
Variable Cases (N=455) Controls (N=527) P-Value
N (%) N (%)
Mean age (years) 61.88 62.34 0.607
Race
Caucasian 438 (96.26) 496 (94.12)
African-American 13 (2.86) 14 (2.66)
Other 4 (0.88) 17 (3.22) 0.108
Family history of cancer in first degree relatives
No 96 (21.10) 130 (24.67)
NHL 9 (1.98) 2 (0.38)
Other cancer 350 (76.92) 395 (74.95) 0.030
Case pathology
All B cell 365 (80.22)
 Diffuse large B-cell 135 (36.99)
 Follicular 105 (28.77)
 SLL/CLL 54 (14.79)
 Marginal Zone 30 (8.22)
 Other 41 (11.23)
All T cell 33 (7.25)
NOS 58 (12.75)
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